Aeroallergen sensitization in asthma: genetics, environment, and pathophysiology.
A complex interplay of genetic predisposition and environmental influences results in the clinical picture of allergic asthma. This article addresses recently identified genetic markers and environmental factors that contribute to disease development in asthma. Focus is placed on aspects of the innate immune system, including inherent properties of allergens, the active role of airway epithelium, and the central importance of dendritic cells together with the pathophysiological processes in which these factors interact. Implications of these processes for asthma therapy, with a focus on anti-IgE treatment are also discussed.
Long
Aidan
A
Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard School of Medicine, Boston, Massachusetts, USA. aalong@partners.org
D000393:Air Pollutants / Q000009:adverse effects / Q000276:immunology; D000485:Allergens / Q000276:immunology; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy / Q000235:genetics / Q000276:immunology* / Q000503:physiopathology; D015415:Biomarkers; D003713:Dendritic Cells / Q000276:immunology; D020022:Genetic Predisposition to Disease; D006801:Humans; D007113:Immunity, Innate / Q000235:genetics*; D007114:Immunization; D007073:Immunoglobulin E / Q000276:immunology*; D007249:Inflammation; D000069444:Omalizumab; D020545:Respiratory Mucosa / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology
D000393:Air Pollutants; D000485:Allergens; D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D000069444:Omalizumab; D007073:Immunoglobulin E